X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Australia Creates A Novel Stem Cell Production Technique

    Australia Creates A Novel Stem Cell Production Technique

    U.S. Officials Clear COVID-19 Jab For Infants, Preschoolers

    U.S. Officials Clear COVID-19 Jab For Infants, Preschoolers

    Bispecific Blood Cancer Drug By Roche Globally Approved

    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    In DELIVER Phase III Study, Farxiga Achieved Primary Outcome

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Australia Creates A Novel Stem Cell Production Technique

    Australia Creates A Novel Stem Cell Production Technique

    U.S. Officials Clear COVID-19 Jab For Infants, Preschoolers

    U.S. Officials Clear COVID-19 Jab For Infants, Preschoolers

    Bispecific Blood Cancer Drug By Roche Globally Approved

    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    In DELIVER Phase III Study, Farxiga Achieved Primary Outcome

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia

Content Team by Content Team
22nd December 2021
in Drug Development, News

Eisai Co., Ltd. announced it has entered into an agreement with Gilead Sciences, Inc. for the commercialization and distribution of filgotinib (generic name, product name: Jyseleca), an oral, JAK1 preferential inhibitor for indications of rheumatoid arthritis (RA), ulcerative colitis, and Crohn’s disease in Asia (South Korea, Taiwan, Hong Kong and Singapore). In December 2019, Eisai signed a partnership agreement with Gilead Sciences K.K., a Japanese subsidiary of Gilead, for the distribution and co-promotion of filgotinib in Japan.

Under the terms of the new agreement, Eisai will obtain an exclusive marketing right for filgotinib in South Korea, Taiwan, Hong Kong and Singapore from Gilead. Gilead has received approval for the treatment of RA in Taiwan and has applied for approval of filgotinib for the treatment of RA in South Korea. Following approvals, Eisai will take over the manufacturing and marketing licenses for filgotinib from Gilead in South Korea and Taiwan. In Hong Kong and Singapore, Eisai will apply for approval for filgotinib. With this agreement, Eisai will pay Gilead a contractual up-front payment, as well as regulatory milestones and sales milestones.

Filgotinib is a once-daily, oral, JAK1 preferential inhibitor. In Japan, filgotinib has been approved for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have had an inadequate response to conventional therapies. In April 2021, Gilead Sciences K.K. applied for an additional indication of filgotinib as a treatment for patients with moderate to severe active ulcerative colitis.

Eisai will leverage its strong business foundation throughout Asia, provide new treatment options for patients with rheumatoid arthritis and inflammatory bowel disease, and contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients their families, and healthcare providers.

About filgotinib

Filgotinib is a once-daily, oral, JAK1 preferential inhibitor. In Japan, filgotinib has been approved for the treatment of RA (including prevention of structural joint damage) in patients who have had an inadequate response to conventional therapies. In April 2021, Gilead Sciences K.K. applied for an additional indication of filgotinib as a treatment for patients with moderate to severe active ulcerative colitis.

In addition, filgotinib has been approved in the European Union and Great Britain for the treatment of adults with moderate to severe active rheumatoid arthritis who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). Filgotinib has also been approved in the European Union for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Applications have been submitted to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with moderately to severely active ulcerative colitis and are currently under review.

About the market for biological products South Korea, Taiwan, Hong Kong and Singapore

The market of biological products in 2020 in South Korea, Taiwan, Hong Kong and Singapore is approximately US $ 400 million, accounting for approximately more than 80% of the total market for biological products in Asia (Hong Kong, India, Indonesia, South Korea, Malaysia, Philippines, Singapore, Taiwan, Thailand and Vietnam).(1) Many of biological products are adapted in the treatments for rheumatoid arthritis and inflammatory bowel disease.

Previous Post

CSafe Global Announces Acquisition of Softbox Systems to Create the Global Leader in Temperature-Controlled Shipping Solutions

Next Post

Hyris fully embraces the Immunology sector to better fight COVID-19 and beyond, presenting its new, disruptive T-Cell test to the international conference A-Wish

Related Posts

Lonza To Construct $518mn Fill-Finish Plant In Switzerland
Manufacturing

Lonza To Construct $518mn Fill-Finish Plant In Switzerland

8th July 2022
Pfizer And Touchlight Enter Into A Patent Collaboration
Manufacturing

Pfizer And Touchlight Enter Into A Patent Collaboration

8th July 2022
AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged
Manufacturing

AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged

8th July 2022
Paxlovid Allowed By FDA To Sell At Certified Pharmacies
Manufacturing

Paxlovid Allowed By FDA To Sell At Certified Pharmacies

8th July 2022
Deloitte Believes Mature R&D Firms Reap Enterprise Value
Manufacturing

Deloitte Believes Mature R&D Firms Reap Enterprise Value

7th July 2022
Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
Next Post
Hyris fully embraces the Immunology sector to better fight COVID-19 and beyond, presenting its new, disruptive T-Cell test to the international conference A-Wish

Hyris fully embraces the Immunology sector to better fight COVID-19 and beyond, presenting its new, disruptive T-Cell test to the international conference A-Wish

Latest News

Lonza To Construct $518mn Fill-Finish Plant In Switzerland
Manufacturing

Lonza To Construct $518mn Fill-Finish Plant In Switzerland

8th July 2022
Pfizer And Touchlight Enter Into A Patent Collaboration
Manufacturing

Pfizer And Touchlight Enter Into A Patent Collaboration

8th July 2022
AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged
Manufacturing

AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged

8th July 2022
Paxlovid Allowed By FDA To Sell At Certified Pharmacies
Manufacturing

Paxlovid Allowed By FDA To Sell At Certified Pharmacies

8th July 2022
Deloitte Believes Mature R&D Firms Reap Enterprise Value
Manufacturing

Deloitte Believes Mature R&D Firms Reap Enterprise Value

7th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In